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Next generation bone tissue 
engineering: non-viral miR-
133a inhibition using collagen-
nanohydroxyapatite scaffolds 
rapidly enhances osteogenesis
Irene Mencía Castaño1,2,3, Caroline M. Curtin1,2,3, Garry P. Duffy1,2,3 & Fergal J. O’Brien1,2,3
Bone grafts are the second most transplanted materials worldwide at a global cost to healthcare 
systems valued over $30 billion every year. The influence of microRNAs in the regenerative capacity 
of stem cells offers vast therapeutic potential towards bone grafting; however their efficient delivery 
to the target site remains a major challenge. This study describes how the functionalisation of porous 
collagen-nanohydroxyapatite (nHA) scaffolds with miR-133a inhibiting complexes, delivered using 
non-viral nHA particles, enhanced human mesenchymal stem cell-mediated osteogenesis through 
the novel focus on a key activator of osteogenesis, Runx2. This study showed enhanced Runx2 and 
osteocalcin expression, as well as increased alkaline phosphatase activity and calcium deposition, thus 
demonstrating a further enhanced therapeutic potential of a biomaterial previously optimised for bone 
repair applications. The promising features of this platform offer potential for a myriad of applications 
beyond bone repair and tissue engineering, thus presenting a new paradigm for microRNA-based 
therapeutics.
Bone grafts are second only to blood transfusions on the list of transplanted materials worldwide at a global cost 
to healthcare systems valued at over $30 billion every year1. Standard repair strategies include autografts and 
allografts but are associated with a number of concerns such as limited tissue volume, risk of rejection as well as 
chronic pain2. Alternatively, the field of tissue engineering aims to regenerate damaged tissues, instead of replac-
ing them, by developing biological substitutes that restore, maintain or improve tissue function. The field relies 
extensively on the use of stem cells in combination with porous 3D scaffolds that house the cells and provide the 
appropriate environment for the regeneration of tissues and organs. To enhance their regenerative potential, 
scaffolds can be specifically tailored to serve as localised delivery depots that release therapeutics in a controlled 
manner to further enhance bone healing.
The emerging field of RNA interference (RNAi), in the form of microRNAs (miRNAs), offers potential in the 
novel development of next generation bone tissue engineering therapeutics based on their ability to influence 
stem cell fate decisions3. miRNAs are approximately 22 nucleotides long in their mature form and have the ability 
to silence protein expression. These miRNAs offer distinct therapeutic advantages in comparison to other nucleic 
acid therapeutics as the imperfect target binding of miRNAs allows for a multi-targeting effect on complex signal-
ling pathways4. Application of miRNAs thus increases the number of avenues that can be manipulated simultane-
ously, potentially incurring an enhanced therapeutic outcome. A range of synthetic options have been developed 
to both imitate and inhibit miRNA function, i.e. mimics and antagomiRs, which widens the therapeutic interest 
in miRNAs to ultimately knockdown or enhance levels of the protein target respectively4. Consequently, a num-
ber of areas of regenerative medicine, including bone regeneration–the particular focus this study, have recently 
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explored the role of a series of miRNAs by inhibiting or mimicking their function, thereby generating interest in 
their therapeutic use for tissue repair5,6.
A critical consideration when applying RNAi to tissue repair relates to the need for the combined application 
of a delivery vector and a 3D scaffold in order to locally trigger a temporal therapeutic effect. Delivery vectors, 
typically nanoparticles, mediate uptake of the RNAi cargo, but rapid in vivo clearance of nanoparticles from 
target locations, owing to their small size, limits their local effects to occur over short time periods7. Hence, the 
incorporation of nanoparticles in clinically-translatable 3D scaffolds -designed for tissue regeneration- as miRNA 
delivery systems holds great promise to fully realise the therapeutic potential of miRNAs for tissue engineering 
applications8.
Recently, 3D scaffolds incorporating viruses belonging to the baculovirus and lentivirus families have showed 
promising functional delivery of pre-miRs and miR-inhibitors to adipose derived stem cells (ASC) of human 
and rat origin respectively, in both cases achieving a noteworthy effect in the repair of bone defects in vivo9,10. 
However, clinical applicability of viral-based miRNA delivery methods is still limited by the threat of adverse 
immune responses in patients and the risk of insertional mutagenesis11. Alternatively, non-viral commercial 
lipid-based delivery vectors have recently been incorporated in 3D platforms to enhance miRNA-mediated oste-
ogenesis in rat12, mouse13 and human bone marrow mesenchymal stem cells (hMSCs) respectively14. However, 
cell membrane damage associated with the detergent effect of lipid vectors has been referred to as a limiting 
factor for their clinical application15. With this in mind, we turned to ceramic-based hydroxyapatite nanopar-
ticles (nHA) as vectors, focussing on their major advantage, that is proven high biocompatibility16. nHA offers 
additional advantageous properties for use in bone regeneration applications due to the chemical mimicry to 
the inorganic component of bones, as well as its demonstrated osteo-conductive and osteo-inductive properties 
in vitro and in vivo17,18. Recent work from our laboratory has developed an innovative bioactive 3D scaffold sys-
tem for miRNA delivery and extensively characterised its structural, biological and functional properties, includ-
ing dose-response uptake studies by flow cytometry19. This system, with excellent efficiency for the delivery of 
both reporter miR-mimics and inhibitors (antagomiRs) to hMSCs19, incorporates non-aggregating nHA particles 
as non-viral vectors embedded within a collagen (coll)-nHA porous scaffold developed in our lab specifically for 
bone repair17,18,20. While composite porous scaffolds containing ceramic and collagen components have shown 
potential in bone tissue engineering20, the need to incorporate additional therapeutic cues within these materials 
is a recurrent hot topic in the field21. Thus, the overall aim of this study was to apply these composite porous scaf-
folds to deliver miRNA-based therapeutics, in order to enhance osteogenesis by hMSCs for the first time.
A small number of studies have focussed on unravelling the role of miRNAs in regulating osteodifferentiation5,6. 
Recent research efforts have identified a selection of miRNAs as osteo-therapeutics, many of which have direct 
targets that only play a secondary role in the osteogenesis pathway22. In contrast, miR-133a has been identified 
as a direct negative regulator of the master transcription factor of osteogenesis, Runx223; hence, the direct rela-
tionship between miR-133a levels and Runx2 expression provides a possibility to target a central activator of 
osteogenesis. Thus in this study, the central regulatory role of miR-133a was speculated to offer a significant ther-
apeutic target. It was hypothesised that localised inhibition of miR-133a levels in hMSCs would increase Runx2 
when using the custom coll-nHA delivery system. Hence, it was proposed that this novel approach, focussed on 
targeting the key transcription factor of the osteogenesis pathway using miRNA technology in hMSCs for the first 
time, may allow a promising enhancement of their osteogenic potential (Fig. 1).
In this study, we specifically aimed to develop the first non-viral, non-lipid 3D miRNA-delivery platform using 
nHA particles to deliver the therapeutic antagomiR-133a within coll-nHA scaffolds engineered specifically for 
bone repair24. This system was capable of manipulating Runx2 levels in hMSCs, importantly using low miRNA 
doses (20 nM) compared to the literature19. This study thus showcases the ability of antagomiR-133a, complexed 
with nHA particles in a formulation termed nanoantagomiR-133a, to significantly enhance Runx2 levels and 
osteogenesis in hMSC monolayer as well as to produce a rapid pro-osteogenic effect in hMSCs in 3D culture 
platforms.
Results and Discussion
Intracellular miRNA level analysis in hMSC monolayer osteogenic culture. The pattern of miR-
133a expression during osteogenesis has not been previously assessed in hMSCs. Hence, we sought to elucidate 
miR-133a expression levels in hMSCs over the course of 14 days comparing standard and osteogenic culture 
(Fig. 2). miR-133a expression continuously increased in the standard (no osteogenic supplements) culture group, 
whereas the osteogenic culture group showed a peak at day 3 but reduced levels at the later timepoints of days 
7 and 14. This pointed to a link between suppression of miR-133a and progression of in vitro osteogenesis, in 
accordance with previous reports for C2C12 mouse myoblasts and primary mouse vascular smooth muscle 
cells23,25. Interestingly, with the nanoantagomiR-133a treatment, a sustained downregulation of miR-133a was 
obtained from day 1, the earliest time point assessed, which demonstrated accelerated downregulation of miR-
133a levels in comparison to untreated cells in osteogenic culture (Fig. 3a). This confirmed the ability of the nano-
miR system to achieve high, maintained silencing effects with a functionality level over 80%, which is consistent 
with that previously reported for this non-viral system19. In summary, this data highlighted the role of miR-133a 
in hMSC osteogenic differentiation and the potent ability of the nHA particles to act as non-viral delivery vectors 
for specific manipulation of intracellular miRNA levels.
Key issues for miRNA-based therapeutics are silencing specificity and deregulation of the RNA-induced 
silencing complex (RISC) machinery by overloading. In order to assess specificity and RISC overload-
ing associated effects, the level of miR-16, which is basally expressed in stem cells, was determined following 
nanoantagomiR-133a treatment (Fig. 3b). Complementary to this, treatment with nanoantagomiR-16 as a 
negative control was introduced to control for specific manipulation of miR-133a levels. Results in both cases 
showed no changes in comparison with the reference group, which received the scrambled (scr) nanoantagomiR 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:27941 | DOI: 10.1038/srep27941
treatment (Fig. 3b,c). Scr miRNA sequences lack canonical targets in the studied species and thus are commonly 
utilised as a negative control for miRNA manipulation experiments. This data was thus indicative of specificity 
and no RISC overloading effects on hMSCs following nanomiR treatment.
Levels of target and osteogenic markers along with mineral deposition was increased in 
nanomiR-treated hMSC osteogenic monolayer culture. To evaluate the effect of downstream direct 
targets as well as the osteogenesis achieved with the nanomiR treatment in monolayer, relative mRNA levels 
were analysed at day 7. Runx2 expression was increased 9-fold with a single dose of the nanoantagomiR-133a 
treatment (Fig. 4a) while a 14-fold increase was found when osteocalcin (OCN) levels were analysed (Fig. 4b). 
Of relevance, miRNA induced effects in protein levels are attributable to changes in mRNA expression in up to 
84% of the genome26,27. Additionally, several miRNAs have reported fine-tuning changes (≤ 3 fold) in the mRNA 
levels of Runx2 and OCN28–31; in contrast, the higher amplitude changes observed in our work may be associated 
with a phenotype-switching role32, more beneficial to trigger enhanced functional osteogenesis. To further assess 
functional osteogenesis, alkaline phosphatase (ALP) activity and calcium deposition in the extracellular matrix 
Figure 1. AntagomiR-133a role in mesenchymal stem cell (MSC) osteodifferentiation. (a) Extracellular 
ligands such as Bone Morphogenetic Proteins (BMPs) and wingless-related integration site family (Wnt) 
proteins initiate complex signaling pathways (green arrows) that activate the Runt-related transcription factor 
2 (Runx2) to initiate differentiation towards a mature osteoblast state, while miR-133a specifically targets and 
inhibits (red brake symbol) Runx2. (b) AntagomiR-133a forms complexes with nHA particles which are either 
delivered to MSCs directly or on porous collagen-nHA scaffolds. They bind to and inhibit miR-133a (black 
arrow and X symbol), diminishing the silencing of Runx2 (faded red brake symbol), which results in higher 
availability of functional levels of Runx2. Runx2 drives MSCs along the osteogenic lineage in progressive 
maturity stages.
Figure 2. qRT-PCR analysis of miR-133a role in hMSC osteogenesis. Comparison of miR-133a intracellular 
levels between cells cultured in standard growth medium versus osteogenic media over the course of 14 days 
demonstrated a natural decrease in miR-133a at later timepoints in osteogenic culture. Mean + standard 
deviation, n = 4, * p < 0.05, * * p < 0.001.
www.nature.com/scientificreports/
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(ECM) were determined and normalised to double stranded (ds)DNA levels, as a surrogate for cell number. 
Significantly enhanced ALP activity was found in the nanoantagomiR-133a treatment, corresponding to a 17.4 
fold increase over untreated cells after 10 days in osteogenic culture (Fig. 4c). Moreover, calcium deposition was 
enhanced in the cells treated with a single dose of nanoantagomiR-133a, as demonstrated by both quantitative 
and histological analysis (Fig. 4d,e). This effect corresponded to a 3.36 and a 2.55 fold change over untreated cells 
respectively at day 10 and 14 (Fig. 4d). Changes in ALP activity induced by manipulation of miRNA levels have 
been assessed with inhibition of miR-133a resulting in a two-fold increase in ALP activity over untreated cells33. 
From the perspective of this project, the detection of 17-fold increase in ALP activity in the nanoantagomiR-133a 
group suggested an encouraging enhanced effect that may be associated to the delivery method utilised in our 
study. Additionally, non-viral delivery RNAi strategies reported a 2-fold increase in calcium deposition by 
human adipose-derived stem cells (hASCs) after 14 days of osteogenic culture when combining lipoplexes with 
Chordin siRNA34 or miR-148b mimic (40 nM)35. Comparatively, the single application of the low dose of 20 nM 
of nanoantagomiR-133a treatment enhanced calcium deposition above that of lipoplex-based delivery after just 
10 days, and remained superior at the endpoint of 14 days, highlighting its significant potential for bone repair.
One surprising result from this study was that negative control miRIDIAN miRNAs, referred to here as scram-
bled (scr), produced unspecific variations in ALP activity and calcium deposition. A similar effect to that observed 
in this study was also obtained in terms of calcium deposition when the scr molecules were delivered to the hMSC 
osteogenic culture using Lipofectamine (data not shown). Of note, scr miRIDIAN controls were titrated to elim-
inate their effect on ALP activity33, and other studies have shown that ALP activity was affected by the treatment 
with scr miRNAs30,31. These commercially available controls encompass a cel-miR-67 based sequence and were 
anticipated to lack targets in mammalian species. However, further BLAST analysis reports 20–30% homology 
of cel-miR-67 in approximately 100 hits of protein-coding sequences within the human genome, thus possible 
unspecific interactions may explain this effect. Nevertheless, the effect of the scr sequence was surpassed by the 
nanoantagomiR-133a treatment, and the specificity of this effect can be related back to the adequate modification 
of mRNA levels of the direct targets assessed.
In summary, this work demonstrated that nanoantagomiR-133a treatment was capable of enhancing levels 
of Runx2 and OCN as well as ALP activity, all crucial indicators for osteogenic differentiation. Additionally, and 
most beneficially from a therapeutic perspective, this study has demonstrated the potent ability of using in-house 
developed nHA particles to deliver antagomiR-133a to hMSCs resulting in rapidly enhanced calcium production 
as early as day 10 of the study.
Analysis of miRNA, mRNA and osteogenic markers along with calcium deposition level in 
hMSC 3D osteogenic culture. Having demonstrated the success of the nHA particles as non-viral vec-
tors for microRNA delivery to hMSCs in 2D, subsequently, hMSCs were cultured in the 3D environment of 
Figure 3. qRT-PCR analysis of miRNA manipulation in hMSC monolayer cultured in osteogenic medium. 
(a) NanoantagomiR-133a treatment demonstrated a maintained functionality with high silencing of miR-133a 
intracellular levels in hMSC monolayer osteogenic culture. (b) NanoantagomiR-16 treatment did not modify 
intracellular miR-133a levels and (c) nanoantagomiR-133a treatment did not modify intracellular miR-16 levels 
demonstrating treatment specificity and indicating no RISC overloading associated effects. Mean + standard 
deviation, n = 4, * p < 0.05, * * p < 0.001, NS = not significant variation.
www.nature.com/scientificreports/
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nanoantagomiR-133a activated coll-nHA scaffolds. These 3D platforms significantly decreased the amount of 
miR-133a available intracellularly in hMSCs to 0.49 ± 0.14 fold after 3 days (Fig. 5a), an effect which was able to 
trigger a 2.74 ± 1.97 fold change increase in Runx2 mRNA at the same timepoint (Fig. 5b). Importantly, the level 
of this effect on Runx2 expression can be noted to surpass that achieved by polyethylenimine (PEI)-mediated 
miR-20a delivery in polyethylenglycol (PEG) hydrogels7, at approximately a 2 fold increase, even when the deliv-
ery efficiency of PEI has been shown to surpass that of nHA18. Furthermore, at a later time point of 7 days, 
downstream osteogenesis markers including alkaline phosphatase (ALP), OCN and EphrinB4 (EPHB4) were 
upregulated 1.3, 1.5 and 2 fold respectively (Fig. 5c–e), which was a significant increase in comparison with the 
levels detected for the cell osteo medium only group. This effect was in line with that reported for CaP-based 
BMP2 plasmid delivery from titanium mesh scaffolds35. Collectively, this data confirmed the ability of coll-nHA 
scaffolds to mediate a substantially competent manipulation of post-transcriptional gene regulation in hMSC in 
3D culture.
Similar to the assessment of osteogenesis in monolayer, calcium deposition in the ECM was evaluated at the 
particularly early timepoint of 14 days for 3D culture, and at 28 days as a final endpoint. Corresponding with the 
effects of nanoantagomiR-133a activated coll-nHA scaffolds at the gene level, calcium deposition was significantly 
increased in comparison to all other control groups at both timepoints tested (Fig. 6a), with levels 80% higher 
than the 3D culture of hMSC in coll-nHA only scaffolds. Moreover, this hallmark effect was also determined 
using a parallel cell source: rat bone marrow derived MSCs (Supplementary Fig. 1). Histological analysis using 
Figure 4. NanoantagomiR-133a treatment enhanced osteogenesis markers in hMSC monolayer. (a)Runx2 
mRNA expression and (b) OCN mRNA relative level were increased in the nanoantagomiR-133a group after 7 
days. (c) Significantly increased ALP activity levels were found in the nanoantagomiR-133a group 10 days after 
treatment. Mean + standard deviation, n = 3, * * p < 0.001. (d) Calcium deposition was markedly increased by 
day 10 and maintained increased calcium levels compared to the control groups at 14 days after treatment with 
nanoantagomiR-133a in osteogenic culture. (e) Alizarin red staining showed calcium deposits at 10 days after 
treatment, scale bar = 100 μ m. Mean + standard deviation, (a,b) n = 4, (c,d) n = 3, * p < 0.05, * * p < 0.001.
www.nature.com/scientificreports/
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alizarin red staining depicted calcium deposition across all groups, which qualitatively increased from the earlier 
to the later timepoint, and importantly, more prominent, denser staining was found in the nanoantagomiR-133a 
treated group at both timepoints (Fig. 6b). To further verify the osteogenic differentiation process, the presence 
of osteocalcin (OCN) at the protein level was assessed by immunofluorescence staining accompanied with DAPI 
labelling. At both 14 and 28 days after hMSC seeding on the nanoantagomiR-133a activated scaffolds, OCN pro-
tein expression was qualitatively increased in comparison to the remaining groups (Fig. 6c). This data correlated 
with the enhanced levels of OCN mRNA determined for nanoantagomiR-133a activated scaffolds in the gene 
analysis (Fig. 5d) and collectively pointed to a robust enhancement of hMSC osteogenesis in 3D scaffold culture.
The observation of less pronounced effects in three-dimensionally (3D) cultured MSCs, in comparison to 
results in monolayer (2D) has been noted in previous reports in the literature20,36. These studies showed the effect 
on ALP and OCN expression, as well as on ALP activity, was reduced to approximately half that detected in 2D37, 
while the effect on calcium deposition was reduced to 20%37 and 70%20 less than in 2D. Remarkably, the reduced 
calcium deposition from 2D to 3D did not prevent this treatment from enhancing bone repair when tested 
in vivo20. A possible explanation for this effect has previously been proposed owing to the 3D scaffold transfection 
relying on the migration of cells throughout the matrix; thus the larger surface area, in comparison to 2D, would 
initially reduce the relative exposure of cells to the transfection complexes38.
In summary, this data pointed to the successful application of nanoantagomiR-133a for miRNA-mediated 
osteogenesis of hMSCs using the coll-nHA scaffolds as localised delivery platforms.
Interestingly, out of the panel of over 30 miRNAs described in the literature to be involved in osteogenesis, 
only 8 have previously been tested as therapeutics to enhance stem cell osteogenesis. In the majority of these the 
cells internalised the miRNAs in advance of seeding9,10,13,14,38,39, ie. the scaffolds are used to deliver transfected/
transduced cells, as opposed to our study, where the scaffolds are used to deliver the miRNAs with a view to 
transfection of autologous host cells – we contend that this is a major benefit and novelty with our study. Hence, 
upon implantation in a preclinical rat defect model the rat’s host cells surrounding the defect would infiltrate into 
the miRNA-activated scaffolds in vivo, as similarly approached using pDNA delivery in other studies18. Of note, 
miR-148b has been studied in three different reports involving the use of several delivery methods including both 
viral and lipid-based vectors9,36,38. While stem cell treatment with miR-148b mimics elicited promising thera-
peutic effects and was linked to triggering enhanced ALP activity, the silencing of a direct target involved in the 
Figure 5. Enhanced osteogenic markers in hMSC 3D culture. (a) miR-133a intracellular levels were 
significantly decreased for hMSCs cultured on the nanoantagomiR-133a activated scaffolds in comparison to 
the scr activated scaffolds over a timecourse of 14 days, demonstrating a high silencing functionality of the 
non-viral based 3D delivery system. (b) Runx2 mRNA expression was upregulated in the nanoantagomiR-133a 
activated scaffold group after 3 days. Mean + standard deviation, n = 5, * p < 0.05. (c) ALP, (d) OCN and  
(e) EPHB4 mRNA expression was upregulated in the nanoantagomiR-133a activated scaffold group after 7 days. 
Mean + standard deviation, n = 4, * p < 0.05, * * p < 0.001.
www.nature.com/scientificreports/
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osteogenic process has not been experimentally validated for this miRNA. Similarly, the direct osteogenic target 
validated for miR-26a, SMAD1, was not studied when miR-26a was assessed for bone repair. Although markers of 
both osteogenesis and angiogenesis were found to be increased in this study, the molecular course of activation of 
such processes was not examined14. Additionally, it is important to note that miRNAs tested as osteo-therapeutics 
so far, with the exception of miR-31, were not validated to target key activators of the osteogenesis pathway, but 
rather intermediate signalling molecules which are part of side signalling pathways in many cases12. Contrary to 
this, the innovative approach evaluated in this study focussed on miRNA-mediated manipulation of the levels of 
Runx2, the transcription factor regarded as the primary driver of the osteogenic pathway. Moreover, by incor-
porating nanoantagomiR-133a complexes in the 3D scaffolds in a cell-free manner, the coll-nHA scaffolds were 
utilised as reservoirs for the localised delivery of the miRNA complexes to the cells, with an associated potential to 
exist as ‘off-the-shelf ’ platforms for bone repair. Future assessment of this system in a pre-clinical animal model of 
bone defect will inform about the potential of this system to improve the regeneration of bony tissue.
Taken together, this study has produced an innovative alternative to existing bone graft treatments and rep-
resents a promising new concept in tissue engineering through the inhibition of miR-133a in hMSCs for the first 
Figure 6. Enhanced mineral matrix deposition in hMSC 3D culture. (a) Calcium normalised to dsDNA 
content confirmed a significant increase in calcium deposition by day 14 in nanoantagomiR-133a activated 
coll-nHA scaffolds and maintained increased calcium levels compared to the control groups after 28 days. 
Non cell-seeded scaffolds were used as a control for the determination of calcium presence in the extracellular 
matrix. Mean + standard deviation, n = 3, * * p < 0.001, #p < 0.001 compared to all other groups. (b) Alizarin 
red staining showed increased calcium deposits in the nanoantagomiR-133a loaded coll-nHA scaffold group at 
14 and 28 days compared to all other groups. Scale bar = 50 μ m. (c) OCN immunofluorescence staining (green) 
after 14 and 28 days in 3D osteogenic culture showed increased protein expression in the nanoantagomiR-133a 
loaded scaffolds in comparison with the control treatment groups. Nuclei depicted in blue, for DAPI staining, 
Scale bar = 50 μ m.
www.nature.com/scientificreports/
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time using hydroxyapatite based delivery on porous collagen-based scaffolds. The results of this study showed 
enhanced stem cell mediated osteogenesis using scaffolds that were miRNA-activated in advance of cell seed-
ing, pointing to the exciting potential of further enhancing the therapeutic application of a biomaterial previ-
ously optimised for bone repair applications. Incorporation of the nanoantagomiR-133a treatment in these 3D 
platforms showcased a successful example of enhanced hMSC osteogenesis through the novel application of a 
miRNA-based strategy focussed directly on a key activator of osteogenesis, Runx2. The significant therapeutic 
efficiency achieved with the use of the beneficial non-viral nHA particles additionally indicated that this vector 
should not be overlooked in the derivation of new therapeutics in the field. Importantly from an overall perspec-
tive, since the nanomiR activated scaffolds continue to exert successful manipulation of MSC gene expression, 
combining this platform technology with miRNAs orchestrating distinct pathways in other tissues opens a wide 
avenue of application to other therapeutic areas beyond bone repair. Moreover, these scaffolds can be tailored 
for delivery of numerous miRNA cargos demonstrating the potential applicability of this platform for a myriad 
of applications, including as advanced 3D pathophysiology in vitro systems for disease modelling, as systems for 
drug discovery or analysis of drug transport and function- thus presenting a new paradigm for both tissue engi-
neering and across the multidisciplinary fields of biomedicine and drug development.
Methods
nanohydroxyapatite (nHA) - miRNA (nanomiR) and miRNA-activated scaffold systems. nHA 
particles were synthesised following an in situ precipitation protocol established previously20. Briefly, a phosphate 
solution (12 mM), containing 0.017% (V/V) Darvan 821A dispersant reagent (RT Vandervilt), was added to an 
equal volume of calcium chloride solution (20 mM) and filtered through a 0.2 μ m filter20. nHA particles (150 μ l) 
were added to a scrambled (scr) or hsa-miR-133a miRIDIAN antagomiR solution (Dharmacon) prepared at a 
final 20 nM concentration per well, following the method developed in-house19. Collagen-nHA (coll-nHA) scaf-
folds were manufactured using a freeze-drying technique as previously reported23,40,41. Briefly, coll-nHA suspen-
sions were prepared at a 1:1 weight ratio by homogenising in-house synthesised nHA particles and collagen type 
I (Integra Life Sciences) within an acetic acid (0.05 M) solution. Coll-nHA suspensions were lyophilised at a final 
freezing temperature of − 40 °C using a VirTis Genesis 25 EL freeze-dryer (Biopharma). Scaffolds were then sub-
jected to dehydrothermal sterilisation, cut into cylindrical discs (8 mm × 4 mm), and chemically cross-linked with 
a solution of 14 mM 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC, Sigma-Aldrich) 
and 5.5 mM N-hydroxysuccinimide (NHS, Sigma-Aldrich). Finally, coll-nHA scaffolds were soak-loaded on both 
sides with in situ prepared nanomiRs (150 μ L total at a 20 nM concentration).
Human mesenchymal stem cell (hMSC) culture. hMSCs from iliac crest bone marrow aspirates of 
healthy human volunteers were kindly provided by REMEDI Galway; all experimental procedures were approved 
by the Clinical Research Ethical Committee at University College Hospital, Galway, and written informed con-
sent was obtained from all subjects. All the bone marrow aspirates were treated in accordance with all the rele-
vant guidelines and regulations, and stringent analysis of cell phenotype was carried out in accordance with all 
the relevant guidelines, following which hMSCs were obtained42. Cells were cultured using low-glucose DMEM 
(Sigma), supplemented with foetal bovine serum (FBS; 10%, Sigma) plus penicillin/streptomycin (1%, Sigma) 
and regularly cleared for mycoplasma contamination tests. Cells (passage 4–6) were used at seeding densities of 
3 × 104 cells per well (6 well plates) for monolayer, and 3 × 105 cells per scaffold for 3D experiments. Complete 
osteogenic media consisted of standard growth medium supplemented with 50 μ g/mL ascorbic acid-2-phosphate, 
10 nM β -glycerophosphate and 100 nM dexamethasone.
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR). qRT-PCR was used to determine 
levels of miR-133a, Runx2, and OCN after transient transfection using the nanomiR method. Briefly, total RNA 
extraction was performed using QIAzol plus a miRNeasy kit (Qiagen) under manufacturer’s instructions. The 
Quantitect Reverse Transcription kit combined with the validated Quantitect primer assays (Qiagen) plus SYBR 
Green master mix (Roche) was applied for the measurement of mRNA levels, and the Taqman miR-PCR assay kit 
(BioSciences) for miR-133a levels. Relative expression normalised to 18S ribosomal RNA was calculated using the 
2(-Δ Δ Ct) method with scr nanomiR treatments set as the reference group.
Mineral deposits quantification. A Calcium Liquicolor kit (Stanbio Laboratories) was used under man-
ufacturer’s instructions for calcium quantification. Calcium content quantified for blank coll-nHA scaffolds 
(non cell-seeded) was subtracted from the content determined for all cell-seeded groups. Absorbance of the 
colour product was read using a Varioskan Flash plate reader (ThermoScientific). Complementarily, the dsDNA 
Quant-iT PicoGreen kit (BioSciences) was used under manufacturer’s instructions using the Varioskan system 
as before.
Histological assessment of calcium deposition. Monolayer samples were fixed using 10% formalin and 
stained with 2% Alizarin red staining. Images were captured using the Leica - LAS V3.6 imaging system (Leica). 
Scaffolds were fixed using 10% formalin and dehydrated using an automatic tissue processor (ASP300, Leica) 
prior to paraffin wax embedding. Serial sections were prepared for histological analysis and rehydrated prior to 
staining with 2% Alizarin red. Digital imaging was carried out using a microscope system (Eclipse 90i plus DS 
Ri1, Nikon) coupled to NIS Elements software.
Osteocalcin immunofluorescence staining. Scaffold sections were permeabilised in 1% Triton 
X100 and blocked using 5% horse serum. Samples were incubated with rabbit polyclonal IgG anti-osteocalcin 
antibody (1:50), FITC- goat anti-rabbit IgG antibody (1:200) (both from Santa Cruz Inc.) and mounted with 
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Fluoroshield-DAPI (Invitrogen). Digital imaging was carried out using the Nikon microscope system as before 
and Image J software was utilised to generate merge images.
Statistical analysis. Experiments were performed in triplicate, unless otherwise specified within figure cap-
tions, and are representative of a minimum of three independent repetitions using two cell donors. Sample size 
was chosen based on established procedures in the lab for this delivery system19 and application17,18. qRT-PCR 
Ct values were subjected to a Grubb’s test for outliers exclusion with 95% confidence interval. SigmaPlot 11.0 
software was used to perform analysis of variance (ANOVA) plus a Tukey post-hoc test following software in-built 
data normality analysis. Two-way of ANOVA was carried out for data studied at several timepoints and one-way 
ANOVA for data assessed at a singular timepoint. p < 0.05 and p < 0.001 were considered significant.
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